160 HEALTH

02656
2.4605.75% ( -0.150 )
Delay Closed: Nov 17, 16:08:13

Valuation

Current ValuationThe current P/E ratio is -14.34, above the reasonable range, cheaper than 2.3% of the time in the past 1 years, and the industry ranks 20/22, the industry Median 6.31.

-14.34xP/E
Stock priceHK$2.46Earnings per shareHK$-0.17

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 6.31x
05101520

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 6.31x
0x10x20x30x40x50x
P/E ratio
Name/Symbol
02427HKGUANZE MEDICAL
-22.61x--HK$1.87B
02656HK160 HEALTH
-14.34x--HK$854.21M
01931HKETHK LABS INC.
-6.16x--HK$529.42M
02211HKUNI HEALTH
-17.27x--HK$406.26M
00673HKCHINA HEALTH
-8.39x--HK$402.27M
09955HKCLOUDR
-0.55x89.93%HK$258.29M
00718HKTAI UNITED HOLD
-0.39x--HK$147.00M
00401HKWANJIA GROUP
-12.36x--HK$121.89M
08156HKSINOPHARM TECH
-10.61x--HK$96.96M
06108HKNEW RAY MEDIC
-3.72x--HK$60.18M
02984HKNEW RAY MED-8K
-4.53x--HK$73.23M
00574HKPASHUN INT'L
-2.04x--HK$35.83M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.